The linked FDA records identify Bard Peripheral Vascular, Inc. as the applicant on two premarket approval entries for the Liverty™ TIPS Stent Graft, both reviewed by the Cardiovascular advisory committee. The original approval, P250050, carries a decision date of September 25, 2026, and the later 30-Day Notice supplement, P250050/S001, carries a decision date of October 23, 2026. The collection snapshot retrieved on November 20, 2026 lists two linked records, one approval and one 30-Day Notice, and those counts describe the linked filings only. [1][2][9]
The Liverty TIPS Stent Graft approval
P250050 was received on November 26, 2025, and approved on September 25, 2026, under decision code APPR. The approval statement describes the device as indicated for the treatment of complications of portal hypertension, and the record lists the generic name as shunt, portosystemic, endoprosthesis, device class 3, product code MIR, with no expedited review flag. The applicant address on the filing is 1625 W. 3rd St., Tempe, AZ. [2][9]
The Summary of Safety and Effectiveness Data describes the ARCH study as a global, prospective, multi-center, single-arm clinical study intended to assess the safety and effectiveness of the Liverty™ TIPS Stent Graft. The same document references bench testing of the delivery system, including thrombogenicity, conducted under FDA 21 CFR Part 58 GLP regulations. [8]
The 30-Day Notice supplement
P250050/S001 was received on September 28, 2026, and decided on October 23, 2026, under decision code OK30. The supplement type is 30-Day Notice, and the stated reason is a process change affecting manufacturer, sterilizer, packager or supplier. The action statement describes a modification to the manufacturing process of the inner ePTFE covering material of the Liverty TIPS Stent Graft. [1]
The supplement record repeats the same applicant, address, product code and cardiovascular advisory committee as the original approval. The collection snapshot counts one OK30 decision and one APPR decision across the two linked records, and the smaller record sample shows the same one-to-one split. [1][2]
Company-published product information
BD publishes a product page for the Liverty™ TIPS Stent Graft that states the same indication for use: treatment of complications of portal hypertension. The page describes tailoring the shunt diameter to the individual patient's hemodynamic needs and refers to a range of covered TIPS stent lengths, with a footnote pointing to data on file at BD in Tempe, AZ. Those product claims originate with the publisher, not with the FDA filings. [6]
A separate recall record
Recall record Z-3275-2026 concerns the EnCor EnCompass Breast Biopsy and Tissue Removal System Console (ENCPCONSOLE) and Driver (ENCPDRIVER) with software, identified by software versions and serial numbers. FDA lists its status as Ongoing, with initiation on August 20, 2026, initial firm notification by letter, and center classification on September 25, 2026. The distribution field describes nationwide U.S. distribution across the listed states. The recalling-firm identity should be checked on this separate recall record. [3]


